[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hintz et al., 1981 - Google Patents

Synthetic hGH causes both increased somatomedin levels and insulin resistance in humans

Hintz et al., 1981

View PDF
Document ID
18291412882903631333
Author
Hintz R
Rosenfeld R
Wilson D
Bennett A
Publication year
Publication venue
Pediatric Research

External Links

Snippet

The supply of human pituitary growth hormone (hGH) available has been limited by the number of donors. Recently, methionyl-hGH (Genentech) has been synthesized by recombinant DNA techniques. We have compared synthetic methionyl-hGH with pituitary …
Continue reading at www.nature.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
US4747825A (en) Apparatus and methodology for pulsed administration of growth promoting agents
Kaplan et al. Clinical studies with recombinant-DNA-derived methionyl-human growth hormone in growth hormone-deficient children
ALBERTSSON‐WIKLAND et al. Daily subcutaneous administration of human growth hormone in growth hormone deficient children
Stewart et al. Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats.
Klinger et al. Three year IGF-I treatment of children with Laron syndrome
AU2010200224B2 (en) GRF Analog Compositions and Their Use
US20090023646A1 (en) GHRH analogues
GOURMELEN et al. Serum levels of insulin-like growth factor (IGF) and IGF binding protein in constitutionally tall children and adolescents
EP0358234B1 (en) Intranasal calcitonin formulations
Maislos et al. The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin.
Wilson et al. Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatomedin response
TAKANO et al. Growth hormone treatment in Turner's syndrome
Hintz et al. Synthetic hGH causes both increased somatomedin levels and insulin resistance in humans
Bierich et al. Stunted growth due to peripheral resistance to somatomedin, a new syndrom
Barron et al. Growth hormone responses to growth hormone-releasing hormine (1–29)-NH2 and a D-Ala2 analog in normal men
Sobel et al. Cell mediated immunity to pituitary extracts in hypopituitarism
Stebbing et al. Efficacy and pharmacokinetics of recombinant DNA derived human growth hormone in rats and monkeys
Blethen et al. Kinetics of somatomedin C/insulin-like growth factor-I (SMC) response to hGH in GH deficient children
Rappaport et al. Discrepancy between the bioactivity and the binding activity of somatomedin in patients with abnormal growth hormone secretion after cranial irradiation
Takano et al. Short-term study of biosynthesized hGH in man
Wit et al. Short-term effect on growth of two doses of GRF 1-44 in children with growth hormone deficiency: comparison with growth induced by methionyl-GH administration
CA2218618A1 (en) Method for treatment of pain
Wehrenberg et al. Effects of growth hormone-releasing factor in the brain
Leger et al. Progressive normalization of growth hormone-binding protein and IGF-I levels in treated growth hormone-deficient children
US5135912A (en) Natriuretic peptides from the pituitary prohormone proopiomelanocortin